# A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies

> **NCT01202370** · PHASE1 · COMPLETED · sponsor: **University of Kentucky** · enrollment: 3 (actual)

## Conditions studied

- Solid Malignancies

## Interventions

- **DRUG:** 7-t-butyldimethylsilyl-10-hydroxycamptothecin

## Key facts

- **NCT ID:** NCT01202370
- **Lead sponsor:** University of Kentucky
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2013-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01202370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01202370, "A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01202370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*